

Leo Lens Pharma Proud to Be Selected as a Connect 2020 Cool Company

Company Recognized by Connect w/ San Diego Venture Group as One of San Diego's Top Performing Start-ups

A Message from Leo Lens Pharma

(May 2020) Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that it was selected as a 2020 Cool Company by Connect w/ San Diego Venture Group. Cool Companies is an annual capital program designed to match San Diego's best technology and life sciences start-ups ready to raise Series A — with quality venture capital. The program selects top tier, local entrepreneurs raising institutional funding, and grants them opportunities for direct access to capital providers. The program regularly attracts over 200 VCs to the region annually. Since 2016, Cool Companies have raised over \$400M, in just Series A institutional funding.

“We received a record number of applications from extraordinary companies for the ‘Cool Companies’ program this year,” said Mike Krenn, CEO of Connect.



Helping Protect Sight



Leo Lens Pharma

A 2020 Cool Company

Leo Lens Pharma has developed the MediPrint™ process, a proprietary printing technology that allows for the sustained, continuous release of ophthalmic drugs via contact lenses. The company's lead proprietary asset is a lens to treat glaucoma. This lens is manufactured with the MediPrint™ process, which allows for the continuous delivery of FDA approved Bimatoprost for 7 days. Leo Lens has already had a successful pre-IND meeting with the FDA to confirm its relatively expedient regulatory strategy and will be submitting an IND for the glaucoma product in 2020.

"We want to thank Connect w/ San Diego Venture Group and the Cool Companies program sponsors for including Leo Lens Pharma in this year's class of Cool Companies and are honored to represent the robust San Diego business community," commented Dan Myers, CEO of Leo Lens Pharma. "This selection further validates the Leo Lens Pharma story. There is a significant unmet need for continuous non-invasive therapy for patients suffering from many ocular diseases, such as glaucoma. Our proven pharmaceutical and ophthalmic management team is excited to move our lead asset to the clinic soon to continue our journey to help many of these patients," he added.

About Leo Lens Pharma

Leo Lens Pharma (Leo Lens) is an emerging San Diego-based pharmaceutical company focused on helping protect sight. Using its proprietary MediPrint™ process, the Company will commercialize a drug-eluting, comfort-enhancing contact lens to treat millions of glaucoma patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression and thousands to suffer from preventable blindness. There is a large unmet need for a better non-invasive treatment option in this \$4B US market. Leo Lens' patented MediPrint™ process offers a unique value proposition for patients, practitioners, strategic partners, and payers. Leo Lens is currently focused on advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product pipeline. For more information please visit www.leolens.com.

About Connect w/ San Diego

Venture Group

Connect is a community nonprofit organization passionate about helping tech and life science entrepreneurs build great companies. Connect serves entrepreneurs throughout their growth journey with a suite of curated programs aimed to help companies grow, gain access to capital, and scale. The national venture capital community is annually presented with 'Cool Companies', San Diego's top-performing start-ups, selected neutrally by our elite community of VCs, angel investors, entrepreneurs, executives, market influencers, and community leaders. We help innovative companies thrive so they can make a meaningful impact on the economic development of the region, and together create a world-class tech ecosystem. For more information please visit [www.https://connect.org/](https://connect.org/).